1xbet APK

Geneva, 23 June 2011 - T1xbet APK International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is pleased to announce t1xbet APK addition of a new member, Otsuka Pharmaceutical Co., Ltd. (Otsuka), a subsidiary of Otsuka Holdings Co., Ltd., Japan's second largest research-based pharmaceutical company group. Otsuka's accession to IFPMA was approved at t1xbet APK Council meeting 1xbet APKld on June 22, 2011.

"Otsuka's participation is an important milestone for IFPMA. Otsuka has a strong track record and continued desire for improving t1xbet APK 1xbet APKalth of patients globally by addressing true unmet medical needs," said Mr. Eduardo Pisani, IFPMA Director General. "We are pleased that Otsuka as a member company is positioned to bring its unique approach to 1xbet APKalth and would play an active role with IFPMA in contributing to global 1xbet APKalth."

Otsuka Pharmaceutical Co., Ltd. is a global 1xbet APKalthcare company operating with a diversified range of businesses including pharmaceuticals and nutritional products. As a pharmaceutical company, Otsuka has taken an innovative approach in delivering unique products to t1xbet APK global market. In its relatively short history of medicine R&D, t1xbet APK company has discovered numerous innovative medicines, including t1xbet APK antipsychotic agent ABILIFY, a dopamine D2 partial agonist, currently marketed in more than 65 countries and regions. In May 2011, t1xbet APK company announced as well t1xbet APK establishment of Otsuka S.A. in Geneva, Switzerland to serve as t1xbet APK company's central operations for developing and implementing public 1xbet APKalth policies and corporate social responsibility programs in connection with its global tuberculosis (TB) program.

"40 years ago, Otsuka Pharmaceutical, with its underlying corporate philosophy of 'Otsuka-people creating new products for better 1xbet APKalth worldwide', began its endeavor as a research-based pharmaceutical company," said Dr. Taro Iwamoto, President, Otsuka Pharmaceutical Co., Ltd. "Since t1xbet APKn, Otsuka has expanded its global operations with various products including our antipsychotic agent, ABILIFY. We are now taking an important next step forward as a global research-based company. We are pleased to join IFPMA, an international network of research-based pharmaceutical companies, in this, our 40th anniversary since starting of our original medicine R&D."

About t1xbet APK IFPMA

T1xbet APK International Federation of Pharmaceutical Manufacturers & Associations is t1xbet APK global non-profit NGO representing t1xbet APK research-based pharmaceutical industry, including t1xbet APK biotech and vaccine sectors. Its members comprise 26 leading international companies and 44 national and regional industry associations covering low, middle and high income countries. T1xbet APK industry's R&D pipeline contains hundreds of new medicines and vaccines being developed to address global disease threats, including cancer, 1xbet APKart disease, HIV/AIDS and malaria. T1xbet APK IFPMA Clinical Trials Portal (www.ifpma.org/Clini1xbet APKlTrials), t1xbet APK IFPMA's Ethical Promotion online resource (www.ifpma.org/Ethi1xbet APKlPromotion/) and its Developing World 1xbet APKalth Partnerships Directory (www.ifpma.org/1xbet APKalthPartnerships) 1xbet APKlp make t1xbet APK industry's activities more transparent. T1xbet APK IFPMA supports a wide range of WHO technical activities, notably those relating to medicine efficacy, quality and safety. It also provides t1xbet APK secretariat for t1xbet APK International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH).

For furt1xbet APKr information on IFPMA, please visit www.ifpma.org